推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
颜色
white to beige
溶解性
DMSO: 20 mg/mL, clear
储存温度
2-8°C
SMILES字符串
CC1=CC=CC2=C1NC=C2C3=NC4=CC=CC=C4C=C3
生化/生理作用
VPC-13566 is Binding Function 3 (BF3)-specific inhibitor of the androgen receptor. VPC-13566 potently inhibits AR transcriptional activity by displacement of the BAG1L peptide from the BF3 pocket. VPC-13566 inhibits the growth of various prostate cancer cell lines including an enzalutamide-resistant cell line and inhibits the growth of AR-dependent prostate cancer xenograft in mice.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Molecular cancer therapeutics, 15(12), 2987-2999 (2016-10-22)
Understanding the impact of BRAF signaling inhibition in human melanoma on key disease mechanisms is important for developing biomarkers of therapeutic response and combination strategies to improve long-term disease control. This work investigates the downstream metabolic consequences of BRAF inhibition
Journal of molecular endocrinology, 63(3), 175-185 (2019-08-14)
Oxidative stress (OS) is a major problem during in vitro culture of embryos. Numerous studies have shown that melatonin, which is known to have antioxidant properties, prevents the occurrence of OS in embryos. However, the molecular mechanisms by which melatonin
Genome biology, 17, 10-10 (2016-01-28)
The androgen receptor (AR) is a pivotal drug target for the treatment of prostate cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR antagonists, such as hydroxyflutamide, bicalutamide, and enzalutamide, target the androgen binding site of the receptor
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门